Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Key Points: Pim2 expression is highly elevated in multiple myeloma and is required for multiple myeloma proliferation. Pim2 phosphorylates TSC2 and modulates mTOR-C1 activity to promote multiple myeloma cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 1×
“The mTOR-C1 pathway integrates inputs from diverse signals, including energy, nutrients, stress, growth factor, and oxygen status, many of which converge on the TSC1/2 complex.(36) PI3K/Akt is by far the best characterized signaling pathway regulating the TSC1/2 complex.”
BackgroundThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986 · cited 1×
“Disrupted binding of Raptor or enhanced binding of Deptor with mTOR-C1 complex are potential mechanisms by which Pim2 might regulate mTOR-C1 pathway activity in MM cells.(15,19) However, we observed no significant alterations of the interaction of Raptor and Deptor with mTOR-C1 complex after Pim inhibition (supplement…”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Previous studies have established feedback activation of p-Akt and p-ERK upon mTOR-C1 suppression by rapalog.(40,41) Interestingly, we did not observe significant effects on p-ERK in MM cells upon Pim inhibition (supplemental Figure 7).”
BackgroundRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 2×
“TSC2 is a guanosine triphosphate (GTP)ase-activating protein for the small G-protein Rheb which, when bound to GTP, activates mTOR-C1.(22,23) Thus, TSC2 is a negative regulator of mTOR-C1 activity.”
BackgroundManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · cited 1×
“The activation of PI3K/Akt leads to phosphorylation of TSC2 on Ser939 andThr1462 to relieve its suppression onmTORC-C1.(37,38) Pim and Akt kinase families have been implicated as playing complementary roles in promoting survival of hematologic cells through common substrates such as BAD.”
BackgroundCarracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · cited 1×
“Previous studies have established feedback activation of p-Akt and p-ERK upon mTOR-C1 suppression by rapalog.(40,41) Interestingly, we did not observe significant effects on p-ERK in MM cells upon Pim inhibition (supplemental Figure 7).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 3×
“The high Deptor levels may potentially provide prosurvival benefit through maintaining PI3K/Akt activation.(15) Interestingly, we observed no correlation of Deptor expression levels with sensitivity to Pim compound treatment in MM cell lines, because we found that KMS-11.”
BackgroundInsulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190 · cited 1×
“In addition, both Pim and Akt are known to directly phosphorylate PRAS40, resulting in the dissociation of PRAS40, an inhibitory component, from the mTORC1 complex.(20,39) However, in the context of MM, we found that p-PRAS40 is more responsive to PI3K/Akt pathway modulation and less sensitive to Pim kinase regulation.”
Background
Cited by
Tracking the embryonic stem cell transition from ground state pluripotency
Kalkan, T., Olova, N., Roode, M., Mulas, C., Lee, H. J., Nett, I., Marks, H., Walker, R., Stunnenberg, H. G., Lilley, K. S., et al. (2017) · Development · doi:10.1242/dev.142711 · Cited by 289
Keeton, E. K., McEachern, K., Dillman, K. S., Palakurthi, S., Cao, Y., Grondine, M. R., Kaur, S., Wang, S., Chen, Y., Wu, A., et al. (2014) · Blood · doi:10.1182/blood-2013-04-495366 · Cited by 254
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
Luszczak, S., Kumar, C., Sathyadevan, V. K., Simpson, B. S., Gately, K. A., Whitaker, H. C., & Heavey, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0109-y · Cited by 102
Malone, T., Schäfer, L., Simon, N., Heavey, S., Cuffe, S., Finn, S., Moore, G., & Gately, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107454 · Cited by 33
Liu, Z., Liu, H., Yuan, X., Wang, Y., Li, L., Wang, G., Song, J., Shao, Z., & Fu, R. (2018) · Oncology Letters · doi:10.3892/ol.2018.7865 · Cited by 19
“These results were consistent with previous studies that demonstrated that Pim-2 was widely expressed in various types of cancer (11-13).”
Self-citation
Metadata
- Authors
- Lu, J., Zavorotinskaya, T., Dai, Y., Niu, X.-H., Castillo, J., Sim, J., Yu, J., Wang, Y., Langowski, J. L., Holash, J., Shannon, K., & Garcia, P. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-29
- Volume
- 122
- Issue
- 9
- Pages
- 1610-1620
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2087815009
- Cited by
- 163
- References
- 51
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. https://app.cochat.ai/papers/10.1182/blood-2013-01-481457
- The paper
- Lu, J., Zavorotinskaya, T., Dai, Y., Niu, X.-H., Castillo, J., Sim, J., Yu, J., Wang, Y., Langowski, J. L., Holash, J., Shannon, K., & Garcia, P. D. (2013). Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. https://doi.org/10.1182/blood-2013-01-481457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.